Sanofi's Cabazitaxel Swiftly Approved, But Launch Date Is Uncertain
This article was originally published in The Pink Sheet Daily
Executive Summary
Price of next-generation chemotherapy for prostate cancer will be in line with 14 years of development and value to patients, says Sanofi.